Skip to main content

Gastroesophageal Reflux Disease

This study is currently active

Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common gastrointestinal diseases. Per the Montreal definition, GERD is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The term GERD covers a spectrum of conditions, including NERD, erosive esophagitis (EE), and Barrett’s esophagus. When defining GERD as the presence of at least weekly heartburn and/or regurgitation, epidemiological studies reported prevalence estimates of 18.1% to 27.8%, 8.8% to 25.9%, and 2.5% to 7.8% in North America, Europe, and East Asia, respectively.

This trial is a medication approved in Japan and looking for approval in the US. Study is 28 weeks with 7 office visits. The study will require and endoscopy if screening is passed. Endoscopy is when a tube is put into the esophagus to rule on ulcers or cancer. No cost for procedures and compensation up to $785.

Participate in a Study

Submit the form and a clinical study expert will get in touch with you.

Want to know more about our clinical trials?